Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol
DiscussionAlongside a parallel MILI study being conducted by collaborators at the National Cancer Institute (NCI), MILI is the first prevention trial to be conducted in this high-risk group. The MILI study provides a unique opportunity to evaluate the efficacy of metformin as a chemopreventive alongside exploring its m echanism of anticancer action and the biological process of mutated P53-driven tumourigenesis.Trial registrationISRCTN16699730. Registered on 28 November 2022. URL:https://www.isrctn.com/ EudraCT/CTIS number 2022-000165-41.
Source: Trials - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Diabetes | Endocrinology | Fortamet | Metformin | Neurology | Oral Cancer | Research | Study | Toxicology